<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030680</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62991-22998</org_study_id>
    <secondary_id>EORTC-62991</secondary_id>
    <secondary_id>EORTC-22998</secondary_id>
    <nct_id>NCT00030680</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Aggressive Fibromatoses</brief_title>
  <official_title>Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients&#xD;
      who have aggressive fibromatoses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of moderate-dose radiotherapy, in terms of local control, in&#xD;
           patients with aggressive fibromatoses.&#xD;
&#xD;
        -  Determine the acute and late side-effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive radiotherapy 5 days a week for 5.5 weeks for a total of 56 Gy in 28&#xD;
      fractions.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Local control as assessed by MRI at 3 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC 2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as assessed by MRI</measure>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Desmoid Tumor</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive fibromatoses arising in any site&#xD;
&#xD;
               -  Primary, recurrent, or progressive disease that is inoperable or requires a major&#xD;
                  operation resulting in a large functional or cosmetic deficit or mutilation&#xD;
&#xD;
                    -  Progressive disease defined as at least 20% increase in tumor size on 2 MRI&#xD;
                       scans within 1 year after any prior therapy except radiotherapy OR&#xD;
&#xD;
               -  Incompletely resected tumor with gross residual disease not suitable for further&#xD;
                  surgery&#xD;
&#xD;
                    -  Resected within the past 3 months&#xD;
&#xD;
          -  Lesions must be suitable for radiotherapy&#xD;
&#xD;
               -  No bulky intra-abdominal disease in close relation to small bowel&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No conditions that would preclude study follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior endocrine therapy allowed&#xD;
&#xD;
          -  No concurrent endocrine therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to indicator lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior isolated limb perfusion with tumor necrosis factor&#xD;
&#xD;
          -  No concurrent isolated limb perfusion with tumor necrosis factor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. B. Keus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arnhems Radiotherapeutisch Instituut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schnabel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Stadt Ludwigshafen am Rhein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnhems Radiotherapeutisch Instituut</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic - Locatie Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>NL-6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bernard Verbeeten Instituut</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>desmoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

